JP Morgan Healthcare Conference
Supercharging a New FDA: Marty Makary on Science, Power & Patients adds the conference as the setting for Dave Friedberg’s All-In interview with Marty Makary. The source treats the venue as a global biotech crossroads where FDA speed, U.S.-China competition, clinical-trial reform, and public-health trust matter to founders, investors, and regulators at once.
The JP Morgan Healthcare Conference appears in E227｜美国医疗市场AI争夺战：巨头押注，创业公司能赢吗？ as the annual industry context where 张璐 / Zhang Lu observed a shift in healthcare AI sentiment. She says large pharmaceutical and healthcare companies had moved from asking whether AI should be integrated toward treating integration as necessary.
The conference matters in this wiki as an adoption-signal node rather than as a detailed event history. It anchors the episode’s claim that healthcare AI is no longer only a future concept or speculative demo category.
Connections
- Marty Makary, FDA, All-In, and FDA Review Modernization - regulatory reform branch added by the Makary interview.
- 张璐 / Zhang Lu and Fusion Fund — source of the conference observation.
- Eli Lilly, Nvidia, OpenAI, and Anthropic — companies connected to the adoption cycle discussed in the episode.
- Healthcare AI Infrastructure and Medical AI Workflow Integration — practical integration direction emphasized by the source.